These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 12591976)

  • 1. Dosing study seen as victory for clinical trials, mathematical models.
    Tuma RS
    J Natl Cancer Inst; 2003 Feb; 95(4):254-5. PubMed ID: 12591976
    [No Abstract]   [Full Text] [Related]  

  • 2. [Role of G-CSF for breast cancer chemotherapy].
    Suzuki Y; Saito Y; Tokuda Y
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():572-4. PubMed ID: 17679213
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
    Nabholtz JM; Cantin J; Chang J; Guevin R; Patel R; Tkaczuk K; Vodvarka P; Lindsay MA; Reese D; Riva A; Mackey J
    Clin Breast Cancer; 2002 Oct; 3(4):268-75. PubMed ID: 12425755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth factor allows effective dose-intensive regimen in advanced breast cancer patients.
    Oncology (Williston Park); 1995 Jul; 9(7):684. PubMed ID: 8924381
    [No Abstract]   [Full Text] [Related]  

  • 5. Adjuvant docetaxel for node-positive breast cancer.
    Noronha V
    N Engl J Med; 2005 Sep; 353(9):954-5; author reply 954-5. PubMed ID: 16136712
    [No Abstract]   [Full Text] [Related]  

  • 6. Low-dose filgrastim in patients with breast cancer treated with docetaxel, doxorubicin, and cyclophosphamide.
    Ip EJ; Lee-Ma A; Troxell LS; Chan J
    Am J Health Syst Pharm; 2008 Aug; 65(16):1552-5. PubMed ID: 18693211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant chemotherapy with TAC (docetaxel, doxorubicin, and cyclophosphamide) in patients with breast cancer--incidence of neutropenic fever outside clinical trials.
    Passos-Coelho JL; Esteves S; Vieira PA; Isidoro M; Ribeiro M; Oliveira J; Moreira AR
    Breast J; 2011; 17(5):539-41. PubMed ID: 21899649
    [No Abstract]   [Full Text] [Related]  

  • 8. Prolonged neutropenia after dose-dense chemotherapy with pegfilgrastim.
    Ishiguro H; Kitano T; Yoshibayashi H; Toi M; Ueno T; Yasuda H; Yanagihara K; Garbo CL; Fukushima M
    Ann Oncol; 2008 May; 19(5):1019; author reply 1019-20. PubMed ID: 18325914
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy.
    Burstein HJ; Parker LM; Keshaviah A; Doherty J; Partridge AH; Schapira L; Ryan PD; Younger J; Harris LN; Moy B; Come SE; Schumer ST; Bunnell CA; Haldoupis M; Gelman R; Winer EP
    J Clin Oncol; 2005 Nov; 23(33):8340-7. PubMed ID: 16293865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma.
    Grigg A; Solal-Celigny P; Hoskin P; Taylor K; McMillan A; Forstpointner R; Bacon P; Renwick J; Hiddemann W;
    Leuk Lymphoma; 2003 Sep; 44(9):1503-8. PubMed ID: 14565651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy.
    Scott SD; Chrischilles EA; Link BK; Delgado DJ; Fridman M; Stolshek BS
    J Manag Care Pharm; 2003; 9(2 Suppl):15-21. PubMed ID: 14613340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infusional paclitaxel and weekly vinorelbine chemotherapy with concurrent filgrastim for metastatic breast cancer: high complete response rate in a phase I-II study of doxorubicin-treated patients.
    Ellis GK; Gralow JR; Pierce HI; Williams MA; Livingston RB
    J Clin Oncol; 1999 May; 17(5):1407-12. PubMed ID: 10334525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of FSK0808, filgrastim biosimilar: a multicenter, non-randomized study in Japanese patients with breast cancer.
    Sagara Y; Sato K; Fukuma E; Higaki K; Mizutani M; Osaki A; Takano T; Tokuda Y; Ohno S; Masuda N; Suzuki M; Saeki T
    Jpn J Clin Oncol; 2013 Sep; 43(9):865-73. PubMed ID: 23858037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegfilgrastim: the promise of pegylation fulfilled.
    Crawford J
    Ann Oncol; 2003 Jan; 14(1):6-7. PubMed ID: 12488286
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of metastatic breast cancer with combination paclitaxel/cyclophosphamide.
    Kennedy MJ; Donehower RC; Rowinsky EK
    Semin Oncol; 1995 Aug; 22(4 Suppl 8):23-7. PubMed ID: 7543700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dose mitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involved axillary nodes.
    Fumoleau P; Chauvin F; Namer M; Bugat R; Tubiana-Hulin M; Guastalla JP; Delozier T; Kerbrat P; Devaux Y; Bonneterre J; Filleul A; Clavel M
    J Clin Oncol; 2001 Feb; 19(3):612-20. PubMed ID: 11157010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
    Schippinger W; Holub R; Dandachi N; Bauernhofer T; Samonigg H
    Oncology; 2006; 70(4):290-3. PubMed ID: 16899982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support.
    Wolff AC; Jones RJ; Davidson NE; Jeter SC; Stearns V
    J Clin Oncol; 2006 May; 24(15):2392-4; author reply 2394-5. PubMed ID: 16710041
    [No Abstract]   [Full Text] [Related]  

  • 19. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
    Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
    Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.